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Before the controversies surrounding dysplastic melanocytic nevi are resolved, dermatopathologists must be able
to reliably distinguish dysplastic nevi from common acquired nevi and malignant melanoma. To establish
whether grading of melanocytic dysplasia has any biologic relevance, dermatopathologists must be able to
consistently recognize two or more grades of atypia. We studied the concordance among five dermatopathologists
for recognition and grading of 60 nevomelanocytic lesions. Ten cases from each of the following categories
of melanocytic proliferation were retrieved from the Massachusetts General Hospital files: (1) common melanocytic
nevi, (2) melanocytic nevi with features of dysplastic nevi, (3) dysplastic nevi with slight cytologic atypia, (4) dysplastic
nevi with moderate cytologic atypia, (5) dysplastic nevi with severe cytologic atypia, and (6) primary malignant
melanoma. The slides were reviewed independently; no discussion of diagnostic criteria preceded the review.
Overall concordance for diagnosing dysplastic nevi was 77%, with a kappa statistic of 0.55–0.84. Furthermore, in
grading dysplastic nevi, experienced dermatopathologists had a concordance ranging from 35 to 58% (kappa
value 0.38–0.47). Those with less experience in grading dysplastic nevi had a concordance of 16–65% (kappa value
0.05–0.24). The five observers in this study reliably distinguished dysplastic nevi from common acquired nevi and
malignant melanoma. Further refinement of the criteria for grading of nevomelanocytic dysplasia and experience in
grading are critical for accuracy in subcategorization of dysplastic nevi. Consistent, reproducible subcategorization or
dysplastic nevi is a requisite before the issue of biologic or prognostic relevance of grading (dysplastic nevi) can be
addressed. This study supports the validity of existing criteria for the diagnosis of dysplastic nevi because the
problems in diagnosis were at the limits of the spectrum, namely, discrimination of slightly atypical dysplastic nevi
from common nevi and severely atypical dysplastic nevi from radial growth phase melanoma. J Invest Dermatol
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Recent studies suggest that melanocytic dysplasia is an intermediate
step between common acquired nevi and melanoma [1–7]. If
recognition of dysplastic melanocytic nevi has biologic signifi-
cance, then pathologists must be able to consistently distinguish
dysplastic nevi from melanoma and common nevi. Likewise, if
melanoma risk is related to degree of cytologic atypia in dysplastic
nevi, dermatopathologists must be able to reliably distinguish two
or more grades of melanocyte atypia in dysplastic nevi.
Histologic criteria for dysplastic nevi are not standardized at
present [1]. Most observers emphasize a variable constellation of
architectural features in association with cytologic atypia of
intraepidermal nevomelanocytes [8,9]; however, the need for
cytologic atypia has been dismissed by some pathologists because
such atypia is often subtle and not reproducible. Prior to this report,
two studies showed that dysplastic nevi may be diagnosed with
some consistency by pathologists [8,10,11]. Although criteria for
cytologicatypia are not well established, attempts have been made
to define grades of melanocyte atypia [11].
We examined concordance and interobserver agreement
for the recognition and grading of 60 nevomelanocytic lesions.
The purpose of the study was to assess the agreement among
five observers in (1) distinguishing dysplastic nevi from mela-
noma and common acquired nevi, and (2) grading of dysplastic
nevi.
METHODS
Sixty melanocytic lesions were randomly retrieved from the dermato-
pathology files at Massachusetts General Hospital (MGH) on the basis of
the final reported diagnoses from the previous 6 months. These 60 cases
were composed of 10 lesions from each of the following diagnostic
categories: (1) common acquired melanocytic nevi (limited to lentiginous
junctional and lentiginous compound nevi, three of which had some
features of congenital onset); (2) melanocytic nevi with features of
dysplastic nevi (one of which also had some features of congenital onset);
(3) dysplastic nevi with slight cytologic atypia; (4) dysplastic nevi with
moderate cytologic atypia; (5) dysplastic nevi with severe cytologic
atypia; and (6) primary malignant melanoma in the radial growth phase.
Criteria for diagnosing dysplastic nevi and grading of atypia were based
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on those previously published [7,11,12]. A single representative slide
was chosen from each case by one of the observers (RLB).
The slides were evaluated by the five observers independently. Each
participant was provided with a flowsheet on which they were requested
to check a single diagnosis (of the six listed above) for each case. If a
dysplastic nevus was diagnosed, the observer was requested to grade the
degree of cytologic atypia as slight, moderate, or severe. There was no
discussion of diagnostic criteria prior to the review. Three of the
observers were staff dermatopathologists at MGH with experience
ranging from 6 years to more than 20 years. Two of the observers were
dermatopathologists in training, both pathologists, but each with less
than 2 months experience at an institution where grading of dysplastic
nevi is routinely performed.
The data were analyzed for concordance and by the kappa statistic.
Concordance was evaluated by Kendall’s taub using the Corr procedure
[13]. This is a measure calculated from values of paired observations as to
whether they vary together (in concord) or differently (in discord). The kappa
statistic allows two or more observers to be compared, with an allowance
made for chance. Originally described by Cohen [14], the higher the kappa
value, the better the agreement. Kappa values greater than 0.75 indicate
excellent agreement beyond chance; less than 0.40 indicate poor agreement
beyond chance; and 0.40–0.75 indicate fair to good agreement beyond
chance. Only data with a sensitivity of less than 0.05 are presented.
RESULTS
The distribution of diagnoses by each observer and the final reported
diagnoses are shown in Table I. Because the cases were randomly
selected from the MGH files, there was no selection against difficult
cases. Two cases included posed diagnostic dilemmas. In fact,
each staff member diagnosed these differently. One staff member
(A) called both lesions malignant melanoma; another observer
(B) diagnosed both lesions as dysplastic nevi with severe cytologic
atypia; and the third member of the staff (C) called one lesion a
melanoma and the other a dysplastic nevus with severe cytologic
atypia. Nonetheless, the concordance among the staff for diagnosing
melanoma was 90% with a kappa value ranging from 0.84 to 0.94
(These data are calculated on the ability of observers to distinguish
radial growth phase melanoma from common acquired nevi, nevi
with features of dysplastic nevi, and all three grades of dysplastic
nevi.). The trainees diagnosed melanoma with a concordance of
88% and a kappa value ranging from 0.83 to 1.0. The overall
concordance for discriminating melanoma from all nevi, including
dysplastic nevi, was 90% (Table II).
The statistics for diagnosing dysplastic nevi are shown in Table
II and Table III. These data show the concordance and
interobserver agreement in distinguishing dysplastic nevi from
‘‘nevi’’ on one end of the spectrum and melanoma on the other
end. ‘‘Nevi’’ in these tabulations include common nevi and nevi
with architectural features of dysplasia or cytologic atypia but
with insufficient criteria for the diagnosis of dysplastic nevus. The
overall concordance in diagnosing dysplastic nevi was 77% with
a kappa statistic of 0.55–0.84. The staff diagnosed dysplastic nevi
with a concordance of 69–80% and a kappa statistic of 0.63–0.71,
whereas the trainees showed concordance of 61–88% with a
kappa statistic of 0.55–0.84. Data for trainees include their
agreement with each other, as well as their agreement with staff
members. The concordance and kappa statistic for each observer
pair are shown in Table III.
The data for grading dysplastic nevi are also shown in Table II
and Table III. The overall concordance was 17–65% among
observers and 36–65% with the reported diagnosis (data not
shown). The overall kappa values ranged from 0.05 to 0.47. The
staff dermatopathologists were able to grade dysplastic nevi with
a concordance ranging from 35 to 58% and kappa values ranging
Table I. Diagnosis by Observera
Diagnosis Final A B C D E
Benign nevi (including those with
20 features of dysplasia)
20 23 20 29 21 23
Dysplastic nevi (total) 30 25 30 20 28 27
Slight atypia 10 14 11 12 6 6
Moderate atypia 10 5 10 4 15 14
Severe atypia 10 6 9 4 7 7
Malignant melanoma 10 12 10 11 11 10
aNumber of cases diagnosed in each category by observers A-E; ‘‘Final’’
designates the reported diagnosis. Benign nevi include common nevi and
nevi with some features, either cytologic or architectural, of dysplastic
nevi but not fulfilling all of the criteria.
Table II. Agreement in Diagnosis of Melanocytic
Proliferationsa
Overall Staff Trainees
All nevi (including
dysplastic nevi) versus
melanoma
90%
(0.83–1.0)
84–94%
(0.84–0.94)
83–100%
(0.83–1.0)
Nevi versus dysplastic
nevi versus melanoma
77%
(0.55–0.84)
69–80%
(0.63–0.71)
61–88%
(0.55–0.84)
Dysplastic nevi Slight
versus moderate
versus severe
cytologic atypia
17–65%
(0.05–0.47)
35–58%
(0.38–0.47)
17–65%
(0.05–0.30)
aData for concordance are expressed as percentages. The range of kappa
statistic is listed below in parentheses.
Table III. Interobserver Agreementa
Nevi Versus Dysplastic
Nevi Versus Melanoma
Slight Versus Moderate
Versus Severe
Observer
Pairs
Concordance
(%)
Cohen’s Kappa
Value
Concordance
(%)
Cohen’s Kappa
Value
A versus B 80 0.71 58 0.47
A versus C 69 0.63 35 0.44
B versus C 78 0.67 45 0.38
A versus D 72 0.61 39 0.24
A versus E 62 0.55 17 0.20
B versus D 88 0.84 65 0.23
B versus E 80 0.75 28 0.24
C versus D 74 0.64 38 0.05
C versus E 78 0.69 46 0.13
D versus E 78 0.71 46 0.30
aThe first three rows show agreement among staff dermatopathologists.
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from 0.38 to 0.47 (i.e., showing moderate agreement beyond
chance). In contrast, the trainees graded dysplastic nevi with a
concordance of 16–65% and kappa values ranging from 0.05 to
0.30, indicating poor to moderate agreement beyond chance.
The interobserver agreement for diagnosing severely atypical
dysplastic nevi versus melanoma ranged from 0.41 to 1.0 (staff
0.41–0.81). On the other hand, interobserver agreement for
diagnosis of slightly atypical dysplastic nevi versus nevi with
features of dysplasia ranged from 0.19 to 0.75 (staff 0.40–0.59).
DISCUSSION
Dysplastic nevi have been the topic of much debate and
controversy. Some observers have objected to the term ‘‘dyspla-
sia’’ as applied to nevi and the ‘‘B-K mole’’ or dysplastic nevus
syndrome and have disputed the concept that dysplastic nevi
are common precursors of melanoma [15–17]. Some have also
suggested that many of the histologic changes noted in dysplastic
nevi lack specificity and that melanocytic nevi with such
changes may have a prevalence as high as 53% in the general
population [18].
As a result of the pioneering work of Clark and co-workers
[19,20], Lynch et al [21,22], and others [23,26], it is now
accepted that people with increased numbers of clinically
atypical (dysplastic) nevi are at an increased risk for developing
malignant melanoma, particularly in the context of hereditary
melanoma. Although most workers have defined the dysplastic
nevus using both clinical and pathologic criteria [27,28], the
clinical phenotype of numerous, often grossly abnormal, nevi
appears to be the primary risk factor for melanoma [26]. Partly
because of the lack of agreement on the histopathologic
definition of dysplastic nevi, the association of melanoma risk
with histoligic changes of dysplastic nevi has not been clearly
established [1].
The lack of correspondence between clinically dysplastic nevi
and histologically dysplastic nevi has been well documented
[18,29,30]. This is not surprising, given the lack of universally
accepted criteria for dysplastic nevi. Most notably, many such
studies did not require cytologic atypia for the histologic
diagnosis of dysplastic nevi. This was in part a result of the first
consensus conference on precursor lesions of melanoma, which
did not require melanocytic atypia for the diagnosis of dysplastic
nevi [31]; however, most observers currently emphasize that
melanocytic atypia is an obligatory histopathologic criterion for
the diagnosis of dysplastic nevi [1,8].
The histopathologic criteria used in this study to diagnose
dysplastic nevi have been previously described [1–9,11,12]. Both
architectural and cytologic atypia are required for the diagnosis of
dysplastic nevus; however, only limited quantitative data are
available concerning histopathologic criteria for dysplastic nevi.
Barnhill et al [7] studied the histologic characteristics of the
clinically most atypical nevus removed from each of 153 patients
with non-familial malignant melanoma. Assuming that cytologic
atypia of intraepidermal nevomelanocytes is mandatory for
recognition of dysplastic melanocytic nevi, Barnhill et al identi-
fied nevi with unequivocal cytologic atypia of the latter
population of cells based on two independent, temporally distinct
reviews. Subsequently, 16 architectural features ascribed to
dysplastic nevi were correlated with cytologic atypia by
univariate and multivariate analysis in this series of nevi. On
the basis of results of multivariate analysis, Barnhill et al
concluded that abnormal patterns of intraepidermal melanocytic
proliferation, either lentiginous, irregular junctional nesting, or
both, are essential features of dysplastic nevi in addition to
cytologic atypia. Architectural features of melanocytic dysplasia
emphasized by the World Health Organization (WHO) consensus
report included (1) basilar nevomelanocytic proliferation (extend-
ing at least three rete ridges beyond any dermal nevocellular
component); (2) lamellar fibrosis or concentric eosinophilic
fibrosis; (3) neovascularization; (4) inflammatory response; and
(5) fusion of rete ridges [8]. Criteria for cytologic atypia in
dysplastic nevi have included nuclear enlargement, pleomorph-
ism, hyperchromatism, and prominent nucleoli [7,11,12].
The five dermatopathologists in the present study reliably
distinguished dysplastic nevi from melanoma with a mean
concordance of 90%. This is remarkably similar to the 92%
concordance achieved by the pathologists in the WHO melano-
ma program [8]. The WHO study, however, also included
distinction of dysplastic nevi from common nevi. In the present
study, the dermatopathologists distinguished dysplastic nevi from
common nevi (including those with only some features of
dysplasia) and melanoma with a concordance of 77%. Hence,
without prior discussion of histologic criteria, these observers
reliably made the diagnosis of dysplastic nevus with good to
excellent interobserver agreement beyond chance (kappa value
0.55–0.84).
Observers were more reliable in distinguishing severely
atypical dysplastic nevi from melanoma (kappa value 0.41–1.0)
than in distinguishing slightly atypical dysplastic nevi from nevi
with features of dysplasia (kappa value 0.19–0.75). The greater
difficulty in making the latter discrimination indicates that
recognition of subtle architectural and cytologic alterations is
problematic and possibly not reproducible. In our opinion, there
is a morphologic distinction between dysplastic nevus with severe
cytologic atypia and early radial growth phase malignant
melanoma; however, in some cases this distinction may be
impossible to make because these entities represent two close
points along a spectrum of morphologic changes.
The importance of grading dysplastic nevi rests on the notion
that the biologic behavior of nevi at either end of the spectrum of
dysplasia is different and that dysplastic nevi represent the middle
ground in a continuum from benign common nevi to malignant
melanoma. This is supported by evidence that dysplastic nevi
show both clinical and histopathologic features intermediate
between those of truly benign nevi and overtly malignant
melanomas. Accumulating data from other sources, such as
immunophenotyping with cell surface markers and cytogenetics,
support this idea as well [1,32–34].
The advantage of a three-grade scale over a two-grade scale
may be the allowance of a middle ground for cases where the
degree of atypia is not obviously slight or severe. In fact, both of
the less experienced observers appeared to use this ‘‘safe haven’’
and graded a disproportionate number of dysplastic nevi as
moderate (Table I). The data for grading were also affected by the
lack of discussion of criteria prior to review of the slides. The
terms ‘‘slight to focal moderate’’ and ‘‘moderate to focal severe’’
are used in daily practice by the authors but were not discussed
prior to review. Hence, observers were forced to place the
dysplastic nevi into a single category of ‘‘slight,’’ ‘‘moderate,’’ or
‘‘severe’’ cytologic atypia. This procedure almost certainly
resulted in less agreement for particular lesions.
Consistency in subcategorization of dysplastic nevi is neces-
sary before the issue of biologic and prognostic relevance of
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grading dysplastic nevi can be addressed. First, further refinement
of the criteria for grading of nevomelanocytic dysplasia is needed.
This may include correlation with DNA content, nuclear volume,
and other objective parameters [32–35]. Second, experience in
grading nevomelanocytic dysplasia is necessary.
In the present report, we have shown that even dermato-
pathologists in training are able to recognize melanocyte atypia
(as is required for the diagnosis of dysplastic nevi). Dermato-
pathologists in training were able to distinguish dysplastic nevi
from common acquired nevi and melanoma with a concordance
ranging from 61 to 88% and kappa statistic ranging from 0.55 to
0.84. We also found that (1) grading melanocytic atypia may be
learned (staff were able to grade with greater agreement than
trainees), and (2) greater communication among histopathologists
about criteria and more objective criteria of melanocyte atypia
are needed (there was only moderate agreement in grading
among the staff). On the other hand, grading of atypia is
inherently subjective, and there are limits to the ability to make
such subtle distinctions on a consistent basis. This study also
supports the validity of existing criteria for the diagnosis of
dysplastic nevi because the problems in diagnosis were at the
limits of the spectrum, namely, discrimination of slightly atypical
dysplastic nevi from common nevi and severely atypical
dysplastic nevi from melanoma. Defining the limits of such a
spectrum is difficult and often arbitrary; however, this does not
negate the value of establishing histologic criteria for the
diagnosis and grading of dysplastic nevi.
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